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Preliminary results of Carotid Revascularization
Endarterectomy vs Stenting Trial (CREST)
Thomas L. Forbes, MD, London, Ontario, CanadaPrimary results of the Carotid Revascularization End-
arterectomy vs Stenting Trial (CREST) were recently pre-
sented at the 2010 International Stroke Conference of the
American Heart Association, San Antonio, Texas, February
24-26, 2010. CREST is a prospective multicenter random-
ized controlled trial comparing carotid stenting (CAS) and
carotid endarterectomy (CEA) in both symptomatic
(50% by angiography, 70% by ultrasound, computed
tomography [CT], magnetic resonance angiography
[MRA]) and asymptomatic patients (60% by angiogra-
phy, 70% by ultrasound, 80% by CT, MRA). Patients
were enrolled from 117 participating North American sites.
Randomization was preceded by a credentialing lead-in
phase and trial outcomes were adjudicated in a blinded
fashion. All patients were treated with best medical man-
agement and were followed for up to 4 years. Primary
endpoints were a periprocedural composite of any clinical
stroke, myocardial infarction (MI) or death, and ipsilateral
stroke over the entire follow-up period.
The investigators reported the results (Table) of the study
that includes 2502 patients with amedian follow-up period of
2.5 years (asymptomatic 47%, symptomatic 53%). Mean age
was 69 and there was no difference in age, gender, or cardio-
vascular risk factors. There was no difference between com-
paring carotid artery stenting (CAS) and carotid endarterec-
tomy (CEA) regarding the primary composite endpoint (7.2%
vs 6.8% for CAS and CEA, P  .51). When exploring inter-
actions with this composite endpoint, the investigators ob-
served no effect for symptomatic status or gender. Stroke rate
during the first 30 postoperative days was 4.1% with CAS and
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13002.3% for CEA which was a statistically significant difference.
Additionally, the risk ofmyocardial infarctionwas significantly
less with CAS (1.1%) compared to CEA (2.3%). Regarding
the composite outcome, the investigators found that those
less than 69 years of age fared better with CAS while those
older than 70 had better results withCEA. Stroke rates during
themedian 2.5 years of follow-up did not differ between CAS
and CEA.
Based on the similar composite outcomes between the
two procedures, the investigators concluded that this data
shows similarity in outcomes between CAS and CEAwhich
is influenced by differences in periprocedural stroke and
myocardial infarction (MI).
COMMENTARY
Thomas L. Forbes, MD, London, Ontario, Canada
Information regarding the results of the CREST study
has been long awaited and the investigators have offered us
a preview of what is to come in a more complete report.
There is some promising news that comes out of this report.
First of all, practitioners from 117 study sites should be
commended for achieving such excellent results with low
rates of adverse events with CAS and CEA. Additionally,
CAS and CEA were equally effective in preventing ipsilat-
eral stroke in the follow-up period beyond 30 days with the
assistance of a modern day medical treatment regimen.
These are excellent results.
However, although the 30-day composite outcome rates
were similar between treatment arms, it is difficult to conclude
that CAS and CEA are equivalent options in all patients. The
30-day stroke rate was higher with CAS while myocardial
infarctions weremore common following CEA. Several issues
require clarification, including symptomatic versus asymp-
tomatic presentations, degree of stenosis, and the influence of
age and gender, among others. At first glance, it seems that
symptomatic status and gender did not influence the results.
Because the overall event rates were low, subsequent analyses
may not yield statistically significant results, but even non-
statistically significant trends will assist in answering the im-
portant questions of which patient groups are best treated
with CAS or with CEA.
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Table. Preliminary results of CREST – periprocedural events
CAS CEA Hazard ratio 95% Confidence interval P value
Composite endpoint* 7.2% 6.8% 1.11 0.81-1.51 .51
All strokes 4.1% 2.3% 1.79 1.14-2.82 .01
Major stroke 0.9% 0.6% 1.35 0.54-3.36 .52
MI 1.1% 2.3% 0.5 0.26-0.94 .03
CAS, Carotid artery stenting; CEA, carotid endarterectomy; MI, myocardial infarction.
*Composite endpoint  any clinical stroke, myocardial infarction, or death.
